Payment overview · 2025
General Payments
$302.91
10 reported records · 3 companies
Healthcare provider profile · identity verified
Elena D Spektor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · LOS ANGELES, CA · NPI 1487735668
Verified facts
What the public records show
CMS Open Payments records show Elena D Spektor, M.D. received $302.91 in general payments during 2025 across 10 reported records.
UCB, Inc. accounted for 76.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $230.40 | 76.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.84 | 13.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $32.67 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $302.91 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $230.40 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
42 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 395 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 228 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 34 |
| Celecoxib | Celecoxib | 187 | 24 |
| Alendronate Sodium | Alendronate Sodium | 183 | 25 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 153 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 138 | 19 |
| Febuxostat | Febuxostat | 115 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 105 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 105 | 15 |
| Famotidine | Famotidine | 105 | 22 |
| Lidocaine | Lidocaine | 104 | 13 |
| Allopurinol | Allopurinol | 94 | 13 |
| Metformin Hcl | Metformin Hcl | 92 | 15 |
| Methocarbamol | Methocarbamol | 83 | 18 |
| Ibuprofen | Ibuprofen | 81 | 17 |
| Diclofenac Epolamine | Diclofenac Epolamine | 80 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 17 |
| Januvia | Sitagliptin Phosphate | 76 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 12 |
| Topiramate | Topiramate | 72 | suppressed |
| Furosemide | Furosemide | 70 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 12 |
| Omeprazole | Omeprazole | 69 | suppressed |
| Lisinopril | Lisinopril | 64 | suppressed |
| Methotrexate | Methotrexate Sodium | 64 | 11 |
| Ozempic | Semaglutide | 62 | suppressed |
| Linzess | Linaclotide | 61 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | suppressed |
| Lorazepam | Lorazepam | 55 | suppressed |
| Pregabalin | Pregabalin | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Losartan Potassium | Losartan Potassium | 50 | suppressed |
| Cilostazol | Cilostazol | 47 | suppressed |
| Eszopiclone | Eszopiclone | 43 | suppressed |
| Prolia | Denosumab | 42 | 29 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Enbrel Sureclick | Etanercept | 40 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 11 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 39 | suppressed |
| Benicar | Olmesartan Medoxomil | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Oxycontin | Oxycodone Hcl | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | suppressed |
| Fluocinonide | Fluocinonide | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Dayvigo | Lemborexant | 24 | suppressed |
| Enbrel | Etanercept | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Licart | Diclofenac Epolamine | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 11 |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Captopril | Captopril | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Silenor | Doxepin Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Misoprostol | Misoprostol | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $302.91 · 10 records | UCB, Inc. | Bimzelx, EVENITY, TREMFYA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error